Drug Trial Radar · NCT06975787
Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis
Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
90
Planned (sponsor's estimate)
Start
Dec 22, 2025
Primary completion
Sep 10, 2029
Study completion Sep 10, 2029
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- First posted
- May 16, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is researching a particular group of experimental drugs administered for a short period in the treatment of participants with Lupus Nephritis (LN). The main aim of the current study is to see how safe and tolerable the study drugs are in a long-term follow-up. This is a main study, called an umbrella study, which includes several independent smaller sub-studies. Each of these smaller main sub-studies tests different drugs at the same time, all aimed at treating LN. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)
Conditions
- Lupus Nephritis (LN)
Interventions
VonsetamigDrug
Administered as per the protocol
OdronextamabDrug
Administered as per the protocol
Primary outcomes
What the sponsor says the trial is designed to measure.
- Occurrence of Dose Limiting Toxicities (DLT)Time frame: Up to 56 days
- Occurrence of Treatment Emergent Adverse Events (TEAEs)Time frame: Through week 76
- Severity of TEAEsTime frame: Through week 76
Locations
20 sites in 6 countries. Site status is shown where the registry gives one.
University of California San Francisco - Zuckerberg San Francisco General
San Francisco, California · Recruiting
University of Florida
Gainesville, Florida · Recruiting
Mayo Clinic
Rochester, Minnesota · Recruiting
Baylor College of Medicine
Houston, Texas · Recruiting
Centre Hospitalier Universitaire (CHU) Bordeaux
Bordeaux, New Aquitaine, France · Recruiting
University Medical Center of the Johannes Gutenberg-University Mainz
Mainz, Germany · Recruiting
University Hospital Regensburg
Regensburg, Bavaria, Germany · Recruiting
Seoul National University Hospital
Seoul, South Korea · Recruiting
Samsung Medical Center
Seoul, South Korea · Recruiting
Yonsei University College of Medicine, Severance Hospital
Seoul, South Korea · Recruiting
Hallym University Sacred Heart Hospital
Anyang-si, Gyeonggi-do, South Korea · Recruiting
Hospital Gregorio Maranon
Madrid, Spain · Recruiting
Hospital Universitario 12 de Octubre
Madrid, Spain · Recruiting
Hospital Regional Universitario de Malaga
Málaga, Spain · Recruiting
Hospital Universitario Virgen del Rocio
Seville, Andalusia, Spain · Recruiting
Clinica Universidad de Navarra
Pamplona, Navarre, Spain · Recruiting
Changhua Christian Hospital
Changhua, Taiwan · Recruiting
Taichung General Veterans Hospital
Taichung, Taiwan · Recruiting
National Taiwan University Hospital
Taipei, Taiwan · Recruiting
Taipei Veterans General Hospital
Taipei, Taiwan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.